

Table SII. Logistic regression on outcome (reference = recovery) univariate and multivariate

Characteristic (reference)	Bivariate analysis <i>n</i> = 334 (unadjusted)			Multivariate analysis <i>n</i> = 203 (adjusted to sex and age)		
	OR (95% CI)	<i>p</i> -value	NR	(OR 95% CI)	<i>p</i> -value	NR
Sex (female)	2.23 (0.86–5.76)	0.10	57	2.57 (0.93–7.08)	0.069	39
Age (≥28 vs. ≤27 years)	2.29 (0.88–6.01)	0.09	167	2.95 (1.07–8.11)	0.04	39
GNI affluence (affluent)	6.72 (1.57–28.66)	0.01	0	4.11 (1.13–14.99)	0.03	39
Type of indication (chronic inflammatory dermatoses)			36			41
Leprosy	3.69 (0.85–16.02)	0.08		5.14 (1.09–24.27)	0.04	
Other infectious entities	2.33 (0.31–17.69)	0.41		2.38 (0.30–19.16)	0.41	
Other non-infectious entities	Ø ^a	nc		Ø ^a	NC	
Dapsone dose (100 mg/day)			73			51
<100 mg/day	0.40 (0.05–3.07)	0.37		0.45 (0.05–3.81)	0.46	
>100 mg/day	0.36 (0.05–2.81)	0.33		0.49 (0.06–4.13)	0.51	
Co-medication (not)	1.19 (0.50–2.81)	0.69	36	1.89 (0.50–7.12)	0.35	49
Latency (≤20 day)			171			47
21–28 days	6.37 (0.76–53.10)	0.08		4.95 (0.56–43.49)	0.15	
29–35 days	3.77 (0.37–38.09)	0.33		3.60 (0.35–37.49)	0.28	
≥36 days	7.22 (0.80–65.34)	0.06		7.64 (0.80–72.84)	0.077	
Completeness of HR ^b (not)	2.69 (0.74–9.78)	0.13	90	1.32 (0.32–5.41)	0.70	72
Fever (absent)	0.87 (0.10–7.17)	0.89	48	0.63 (0.06–6.47)	0.70	41
Lymphadenopathy (absent)	1.57 (0.13–2.45)	0.07	68	0.57 (0.13–2.45)	0.45	74
Hepatitis (absent)	8.20 (1.10–61.39)	0.04	39	3.12 (0.38–25.52)	0.29	50
Mucosal involvement (absent)	10.96 (1.31–91.99)	0.03	208	Ø ^c	NC	144
Dapsone cessation (immediately to HS onset)			83			66
Time point unspecified	1.49 (0.54–4.14)	0.44		5.74 (1.33–24.72)	0.02	
Delayed to HS onset	1.88 (0.28–6.15)	0.30		1.12 (0.21–6.03)	0.89	
Systemic glucocorticosteroid therapy (not)	1.22 (0.28–6.15)	0.73	131	0.53 (0.09–2.99)	0.47	84

HR: hypersensitivity reactions; OR: odds ratio; CI: confidence interval; NR: not reported; GNI: gross national per-capita income; NC: not calculable.

^aNone of these patients deceased. ^bComplete HR: presence of all 4 cardinal symptoms (fever, lymphadenopathy, hepatitis, skin symptoms). ^cAll deceased patients with mucosal involvement dropped out of analysis.